Enterprise Value
-218M
Cash
456.8M
Avg Qtr Burn
-66.87M
Short % of Float
10.83%
Insider Ownership
1.34%
Institutional Own.
97.72%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Dapirolizumab Pegol (anti-CD40L) Details Systemic lupus erythematosus, Autoimmune disease | Phase 3 Data readout | |
Rezpegaldesleukin (NKTR-358) Details Autoimmune disease, Atopic dermatitis | Phase 2b Initiation | |
NKTR-255 + Avelumab Details Urothelial carcinoma, Cancer | Phase 2 Data readout | |
NKTR-255 | IL-15R agonist + Cetuximab (Erbitux) | EGFR inhibitor Details Colorectal cancer , Head and neck cancer, Head and neck squamous cell carcinoma, Cancer | Phase 1/2 Data readout | |
NKTR-255 | IL-15 agonist + Daratumumab Details Non-Hodgkin lymphoma, Multiple myeloma, Cancer | Phase 1/2 Data readout | |
Bempegaldesleukin (NKTR-214) + OPDIVO (Nivolumab) Details Solid tumor/s, Cancer | Failed Discontinued | |
Bempegaldesleukin+ KEYTRUDA® (pembrolizumab) (PROPEL) Details Non-small cell lung carcinoma, Cancer | Failed Discontinued | |
Bempegaldesleukin (NKTR-214) + Opdivo (Nivolumab) Details Renal cell carcinoma, Cancer | Failed Discontinued | |
Rezpegaldesleukin (LY3471851) (NKTR-358) Details Autoimmune disease, Systemic lupus erythematosus | Failed Discontinued | |
Bempegaldesleukin (NK-214) + VB10.NEO Details Head and neck squamous cell carcinoma, Cancer | Failed Discontinued | |
NKTR-358 Details Autoimmune disease, Ulcerative colitis | Failed Discontinued | |
Bempegaldesleukin (NKTR-214)+ OPDIVO (Nivolumab) Details Urothelial cancer, Cancer, Bladder cancer | Failed Discontinued | |
Bempegaldesleukin (NKTR 214) + Opdivo (Nivolumab) Details Cancer, Melanoma | Failed Discontinued | |
Bempegaldesleukin (NKTR-214)+ Opdivo (Nivolumab) Details Bladder cancer, Cancer | Failed Discontinued | |
Onzeald (etirinotecan pegol) Details Metastatic breast cancer to brain, Cancer | Failed Discontinued | |
Bempegaldesleukin (BEMPEG) + KEYTRUDA (pembrolizumab) Details Head and neck cancer, Cancer | Failed Discontinued | |
NKTR-262 (with bempegaldesleukin) Details Solid tumor/s, Cancer | Failed Discontinued |